Preliminary results of chemotherapy-induced nausea and vomiting trial
The pilot phase results of the NSW Government funded trial evaluating the potential of cannabis medicines to prevent chemotherapy-induced nausea and vomiting were published in Annals of Oncology in August 2020.
The addition of oral THC:CBD to standard nausea and vomiting medicines was associated with less nausea and vomiting but did cause separate side-effects, which were considered manageable. Most participants in the trial preferred THC:CBD to placebo. Based on these promising results, the trial team plan to recruit an additional 170 participants to complete accrual for the definitive, phase III, parallel group analysis.
Associate Professor Peter Grimison from Chris O'Brien Lifehouse with the University of Sydney is leading the trial, which is a collaboration between the National Health and Medical Research Council (NHMRC) Clinical Trials Centre (the University of Sydney), Chris O'Brien Lifehouse and leading NSW cancer centres.
Further information about the pilot phase results can be found on the NHMRC Clinical Trials Centre website.
For more detailed information about the trial, visit:
- the clinical trials section of the Centre for Medicinal Cannabis Research and Innovation website
- the Australian New Zealand Clinical Trials Registry website.